Five things for pharma marketers to know: Wednesday, February 21, 2018

Share this content:

AbbVie said its elagolix drug was a smash success in its first two trials for uterine fibroids in women. More than 68% of those who received elagolix achieved a clinical response when the drug was combined with low-dose hormone therapy, compared with 8.7% who received the placebo. Results from a second Phase III study are expected soon. (Endpoints)

Mayo Clinic president and CEO Dr. John Noseworthy said he plans to retire at the end of the year. He's been in the role for nine years. Noseworthy's departure will mark the end of a 28-year tenure at the clinic. (Medcity News)

Ipsen said it will begin collaborating with Arix Bioscience, making it the latest in a string of startups to team up with the healthcare company. Arix will offer Ipsen access to its network of advisers and opportunities to invest in its businesses, while Ipsen will bring to the table its R&D and commercial expertise. (FierceBiotech)

The Trump administration is relaxing restrictions on short-term health plans, breaking policy put in place by the Affordable Care Act. Health and Human Services Secretary Alex Azar announced the proposal on Tuesday, saying such plans would offer consumers more choices at a lower cost. (Washington Post)

It's possible to hack medical devices, even pacemakers, according to a study from the Journal of the American College of Cardiology. Although most medical implants have limited connectivity, newer implants have remote monitoring features that could leave patients vulnerable, according to the report. (Medical Xpress)

Share this content:
Scroll down to see the next article